Farther Finance Advisors LLC Has $455,000 Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Farther Finance Advisors LLC lowered its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 36.0% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,013 shares of the medical instruments supplier’s stock after selling 1,131 shares during the quarter. Farther Finance Advisors LLC’s holdings in Becton, Dickinson and Company were worth $455,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in BDX. Bank of Jackson Hole Trust acquired a new stake in shares of Becton, Dickinson and Company during the 4th quarter worth about $25,000. Sierra Ocean LLC acquired a new stake in shares of Becton, Dickinson and Company during the 4th quarter worth about $29,000. REAP Financial Group LLC increased its position in shares of Becton, Dickinson and Company by 75.3% during the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after purchasing an additional 55 shares in the last quarter. Picton Mahoney Asset Management increased its position in shares of Becton, Dickinson and Company by 61.4% during the 4th quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier’s stock worth $32,000 after purchasing an additional 54 shares in the last quarter. Finally, Nexus Investment Management ULC acquired a new stake in Becton, Dickinson and Company in the 1st quarter valued at about $34,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Down 1.4%

Shares of NYSE:BDX opened at $172.06 on Monday. Becton, Dickinson and Company has a one year low of $163.33 and a one year high of $251.99. The company has a 50 day moving average of $183.03 and a 200-day moving average of $212.95. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.13 and a quick ratio of 0.63. The stock has a market cap of $49.31 billion, a price-to-earnings ratio of 28.58, a P/E/G ratio of 1.63 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share for the quarter, topping the consensus estimate of $3.28 by $0.07. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. The business had revenue of $5.27 billion for the quarter, compared to analyst estimates of $5.35 billion. During the same quarter last year, the firm earned $3.17 EPS. Becton, Dickinson and Company’s quarterly revenue was up 4.5% compared to the same quarter last year. On average, sell-side analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, June 30th. Investors of record on Monday, June 9th will be paid a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a yield of 2.42%. The ex-dividend date is Monday, June 9th. Becton, Dickinson and Company’s payout ratio is 79.39%.

Insider Buying and Selling

In other Becton, Dickinson and Company news, EVP David Shan sold 1,166 shares of Becton, Dickinson and Company stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $171.19, for a total value of $199,607.54. Following the transaction, the executive vice president now owns 4,575 shares of the company’s stock, valued at approximately $783,194.25. The trade was a 20.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Michael David Garrison sold 479 shares of Becton, Dickinson and Company stock in a transaction that occurred on Wednesday, April 9th. The shares were sold at an average price of $197.28, for a total transaction of $94,497.12. Following the completion of the transaction, the executive vice president now directly owns 4,887 shares in the company, valued at approximately $964,107.36. The trade was a 8.93% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 2,104 shares of company stock valued at $399,675 in the last 90 days. 0.36% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

BDX has been the subject of several research reports. Wells Fargo & Company cut shares of Becton, Dickinson and Company from an “overweight” rating to an “equal weight” rating in a research report on Thursday, May 1st. Wall Street Zen cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Friday, May 2nd. The Goldman Sachs Group cut shares of Becton, Dickinson and Company from a “buy” rating to a “neutral” rating and set a $192.00 price objective for the company. in a research report on Friday, May 2nd. William Blair cut shares of Becton, Dickinson and Company from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 1st. Finally, Citigroup cut shares of Becton, Dickinson and Company from a “strong-buy” rating to a “hold” rating and lowered their price target for the stock from $217.00 to $185.00 in a research report on Thursday, May 22nd. Eight research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $219.22.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.